7,461 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Horizon Investments LLC

Horizon Investments LLC acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 7,461 shares of the company’s stock, valued at approximately $652,000.

Other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its position in shares of Protagonist Therapeutics by 11.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock valued at $91,000 after buying an additional 146 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the last quarter. Parkman Healthcare Partners LLC increased its position in shares of Protagonist Therapeutics by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock valued at $4,109,000 after purchasing an additional 253 shares during the last quarter. Guggenheim Capital LLC grew its position in Protagonist Therapeutics by 1.6% during the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after acquiring an additional 303 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Protagonist Therapeutics by 138.9% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares during the last quarter. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Up 0.5%

NASDAQ PTGX opened at $99.36 on Friday. The firm has a market cap of $6.39 billion, a price-to-earnings ratio of -54.90 and a beta of 1.89. The business has a 50-day moving average price of $99.40 and a 200-day moving average price of $89.42. Protagonist Therapeutics, Inc. has a twelve month low of $42.85 and a twelve month high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. The firm had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. Research analysts expect that Protagonist Therapeutics, Inc. will post 2.32 EPS for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In related news, Director Harold E. Selick sold 24,000 shares of the stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director directly owned 60,845 shares of the company’s stock, valued at approximately $6,388,725. This represents a 28.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Arturo Md Molina sold 15,000 shares of the stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $104.79, for a total value of $1,571,850.00. Following the transaction, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $8,814,410.85. The trade was a 15.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 138,215 shares of company stock valued at $13,866,186 in the last 90 days. 4.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Citigroup restated an “outperform” rating on shares of Protagonist Therapeutics in a research note on Wednesday. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. Jefferies Financial Group restated a “buy” rating and issued a $121.00 price target on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. HC Wainwright boosted their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Finally, Leerink Partners upped their price objective on Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $113.69.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.